do glp 1 agonists cause pancreatic cancer GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes Risk of pancreatic cancer associated

GLP-1 receptor agonists may reduce risk for obesity-related cancers among people with diabetes compared with dipeptidyl peptidase-4 inhibitors, according to findings scheduled for presentation at ASCO Annual Meeting

doi: 10.3390/ijms2217945

Your insurance my have different criteria for how to access these drugs for non-weight loss purposes, in which case you may reach out to your plan

doi: 10.3390/jcm14134619

Its weight-loss effects are primarily achieved through several mechanisms, including central appetite regulation via hypothalamic pathways enhancing satiety, delayed gastric emptying that prolongs postprandial fullness, improvement of insulin sensitivity and metabolic homeostasis, and reduction of visceral and hepatic fat depots, which may alleviate respiratory mechanical burden and metabolic stress in OSAS (34)

15.3.1 TERNS PHARMACEUTICALS, INC